IGC Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 18 Nov 2026 |
Monitoring Framework
Key Performance Indicators
CALMA Phase 2 Trial Patient Enrollment Quarterly146.0
Quarterly Revenue Quarterly317KTarget: Continued commercialization of white-label formulations
Quarterly Net Loss Quarterly-2.4MTarget: Narrowing losses post-divestiture of non-core assets
Watch Items
- CALMA Phase 2 Topline Data AnalysisTrigger: Completion of data lock and statistical analysis of the 146-patient cohortAction: Publish topline safety and efficacy results for IGC-AD1 in Alzheimer's agitation
- Liquidity and Capital RunwayTrigger: Cash and cash equivalents falling below $200,000Action: Draw down on the $12 million O-Bank credit facility or execute equity/debt financing
- MINT-AD AI Platform Beta LaunchTrigger: Beta software release and initial user onboardingAction: Initiate commercialization and monetization strategies for the AI diagnostic suite
Research as of 20 Jun 2026